Novo Holdings would like to congratulate our portfolio company LAVA Therapeutics (Nasdaq: LVTX) on their recent IPO. LAVA Therapeutics is a biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers to transform cancer therapy.

For further information, please find the full statement here.